Credit rating from CICC: Upgraded Beigene's target price to 175 Hong Kong dollars, expecting third-quarter performance to be encouraging.
BeiGene Is Maintained at Overweight by JP Morgan
BeiGene Analyst Ratings
J.P. Morgan Maintains BeiGene(BGNE.US) With Buy Rating, Raises Target Price to $235
TD Cowen Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $254
TD Cowen Keeps Their Buy Rating on BeiGene (BGNE)
Nomura Adjusts BeiGene's Price Target to HK$174.91 From HK$158.37, Keeps at Buy
BeiGene (688235): ODAC updates PD-1 treatment ESCC+G/GEJ voting progress
Jefferies Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $284
BeiGene Analyst Ratings
JMP Securities Initiates BeiGene(BGNE.US) With Buy Rating, Announces Target Price $288
BofA Securities Maintains BeiGene(BGNE.US) With Hold Rating, Maintains Target Price $198
Hold Rating on BeiGene Amid Mixed Sales Performance and Competitive Pressures
BeiGene (688235): Active expansion of overseas markets can be expected
Morgan Stanley Maintains BeiGene(BGNE.US) With Buy Rating, Cuts Target Price to $307
Morgan Stanley Maintains BeiGene(BGNE.US) With Buy Rating, Cuts Target Price to $307
BeiGene Analyst Ratings
JP Morgan Maintains Overweight on BeiGene, Raises Price Target to $200
J.P. Morgan Maintains BeiGene(BGNE.US) With Buy Rating, Raises Target Price to $200
TD Cowen Initiates BeiGene(BGNE.US) With Buy Rating, Announces Target Price $254